GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (LTS:0QKQ) » Definitions » Piotroski F-Score

Relief Therapeutics Holding (LTS:0QKQ) Piotroski F-Score : 3 (As of Dec. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Relief Therapeutics Holding Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Relief Therapeutics Holding has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Relief Therapeutics Holding's Piotroski F-Score or its related term are showing as below:

LTS:0QKQ' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 4
Current: 3

During the past 13 years, the highest Piotroski F-Score of Relief Therapeutics Holding was 4. The lowest was 1. And the median was 3.


Relief Therapeutics Holding Piotroski F-Score Historical Data

The historical data trend for Relief Therapeutics Holding's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Piotroski F-Score Chart

Relief Therapeutics Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 2.00 1.00 4.00 3.00

Relief Therapeutics Holding Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 4.00 - 3.00 -

Competitive Comparison of Relief Therapeutics Holding's Piotroski F-Score

For the Biotechnology subindustry, Relief Therapeutics Holding's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was CHF-98.18 Mil.
Cash Flow from Operations was CHF-17.61 Mil.
Revenue was CHF6.03 Mil.
Gross Profit was CHF4.30 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was (188.798 + 76.39) / 2 = CHF132.594 Mil.
Total Assets at the begining of this year (Dec22) was CHF188.80 Mil.
Long-Term Debt & Capital Lease Obligation was CHF2.10 Mil.
Total Current Assets was CHF18.30 Mil.
Total Current Liabilities was CHF6.91 Mil.
Net Income was CHF-50.79 Mil.

Revenue was CHF6.08 Mil.
Gross Profit was CHF4.83 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was (251.618 + 188.798) / 2 = CHF220.208 Mil.
Total Assets at the begining of last year (Dec21) was CHF251.62 Mil.
Long-Term Debt & Capital Lease Obligation was CHF2.25 Mil.
Total Current Assets was CHF22.58 Mil.
Total Current Liabilities was CHF10.72 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Relief Therapeutics Holding's current Net Income (TTM) was -98.18. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Relief Therapeutics Holding's current Cash Flow from Operations (TTM) was -17.61. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-98.181/188.798
=-0.52003199

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-50.79/251.618
=-0.2018536

Relief Therapeutics Holding's return on assets of this year was -0.52003199. Relief Therapeutics Holding's return on assets of last year was -0.2018536. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Relief Therapeutics Holding's current Net Income (TTM) was -98.18. Relief Therapeutics Holding's current Cash Flow from Operations (TTM) was -17.61. ==> -17.61 > -98.18 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=2.095/132.594
=0.01580011

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=2.248/220.208
=0.01020853

Relief Therapeutics Holding's gearing of this year was 0.01580011. Relief Therapeutics Holding's gearing of last year was 0.01020853. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=18.304/6.909
=2.64929802

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=22.583/10.716
=2.10740948

Relief Therapeutics Holding's current ratio of this year was 2.64929802. Relief Therapeutics Holding's current ratio of last year was 2.10740948. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Relief Therapeutics Holding's number of shares in issue this year was 11.752. Relief Therapeutics Holding's number of shares in issue last year was 10.57. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4.297/6.033
=0.7122493

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4.831/6.081
=0.7944417

Relief Therapeutics Holding's gross margin of this year was 0.7122493. Relief Therapeutics Holding's gross margin of last year was 0.7944417. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=6.033/188.798
=0.03195479

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=6.081/251.618
=0.02416759

Relief Therapeutics Holding's asset turnover of this year was 0.03195479. Relief Therapeutics Holding's asset turnover of last year was 0.02416759. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+1+0+0+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Relief Therapeutics Holding has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Relief Therapeutics Holding  (LTS:0QKQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Relief Therapeutics Holding Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

Relief Therapeutics Holding Headlines

No Headlines